Moderna, Inc.
A biotechnology company that uses messenger RNA (mRNA) to build medicines and vaccines, best known for Spikevax, its COVID-19 vaccine. Founded in 2010 in Cambridge, Massachusetts, it grew out of the venture-building firm Flagship Pioneering with help from scientists including MIT's Robert Langer. Its name blends "modified" and "RNA"—and conveniently hides the word "modern."
Sold 1.00M
Sold 435.9K
Granted 5.36M · Bought 160.3K · Sold 8.09M
Granted 703
Granted 33.8K · Sold 11.84M
Granted 1.72M · Sold 2.06M
Granted 1.18M · Sold 1.10M
Granted 703 · Bought 84.3K · Sold 2.3K
Granted 156.5K · Sold 34.9K
Granted 128.0K · Sold 10.8K
Granted 36.0K · Sold 3.2K
Sold 575.0K
Granted 2.1K
Granted 78.9K · Sold 134.0K
Granted 18.6K
Granted 908.0K · Sold 900.5K
Granted 18.6K · Sold 6.5K
Granted 9.6K
Granted 1.19M · Sold 1.52M
Granted 4.8K
Granted 4.8K · Sold 361
Granted 300.0K · Sold 300.0K
Granted 6.8K · Sold 3.4K
Granted 2.1K · Sold 939
Granted 2.0K · Sold 1.1K
Granted 267.6K · Sold 331.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Afeyan Noubar +3 co-filersDirector, 10% owner, 10% owner · 22 transactions | — | 84.28Mas of Aug 2020 | — | — | 1.00M |
| Afeyan Noubar +6 co-filersDirector, 10% owner, 10% owner · 8 transactions | — | 51.56Mas of Dec 2018 | — | — | — |
| Afeyan Noubar +4 co-filersDirector, 10% owner, 10% owner · 9 transactions | — | 51.47Mas of Dec 2019 | — | — | 435.9K |
| Bancel StephaneChief Executive Officer, Director · 1554 transactions | — | 48.36M | 5.36M | 160.3K | 8.09M |
| Langer RobertDirector · 3 transactions | — | 11.51Mas of Feb 2023 | 703 | — | — |
| Afeyan NoubarDirector · 321 transactions | — | 6.86M | 33.8K | — | 11.84M |
| Hoge StephenPresident · 735 transactions | — | 1.64M | 1.72M | — | 2.06M |
| Kim Lorence H.Chief Financial Officer · 42 transactions | — | 1.35Mas of Jun 2020 | 1.18M | — | 1.10M |
| Sagan PaulDirector · 6 transactions | — | 494.1Kas of Mar 2025 | 703 | 84.3K | 2.3K |
| Klinger Shannon ThymeChief Legal Officer · 110 transactions | — | 79.3K | 156.5K | — | 34.9K |
| Mock James MChief Financial Officer · 79 transactions | — | 71.4K | 128.0K | — | 10.8K |
| Nader FrancoisDirector · 4 transactions | — | 32.8K | 36.0K | — | 3.2K |
| Kania Edwin M Jr10% owner · 3 transactions | — | 23.8Kas of Jan 2020 | — | — | 575.0K |
| Berenson StephenDirector · 5 transactions | — | 22.2Kas of May 2024 | 2.1K | — | — |
| Nabel Elizabeth GDirector · 12 transactions | — | 19.3K | 78.9K | — | 134.0K |
| Horning SandraDirector · 4 transactions | — | 18.6K | 18.6K | — | — |
| Andres JuanSee remarks · 370 transactions | — | 14.8Kas of Dec 2022 | 908.0K | — | 900.5K |
| Hussain AbbasDirector · 6 transactions | — | 12.1K | 18.6K | — | 6.5K |
| Rubenstein David M.Director · 3 transactions | — | 9.6K | 9.6K | — | — |
| Zaks Tal ZviChief Medical Officer · 415 transactions | — | 5.0Kas of Jun 2021 | 1.19M | — | 1.52M |
| Tallett Elizabeth EDirector · 2 transactions | — | 4.8K | 4.8K | — | — |
| Ruiz IsraelDirector · 1 transaction | — | 4.6Kas of Dec 2018 | — | — | — |
| Lee Jennifer LingChief Accounting Officer · 2 transactions | — | 4.4Kas of Mar 2020 | 4.8K | — | 361 |
| Hutt Peter BartonDirector · 4 transactions | — | 3.9Kas of Nov 2019 | 300.0K | — | 300.0K |
| Garay ArpaChief Commercial Officer · 6 transactions | — | 3.7Kas of Dec 2023 | 6.8K | — | 3.4K |
| Meline David WChief Financial Officer · 6 transactions | — | 2.9Kas of Aug 2022 | 2.1K | — | 939 |
| Burton PaulChief Medical Officer · 4 transactions | — | 954as of Nov 2022 | 2.0K | — | 1.1K |
| Henderson Lori M.General Counsel and Secretary · 62 transactions | — | 901as of May 2021 | 267.6K | — | 331.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -28.11M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.